SEC Tracker
Get the app

Alumis ALMS

Alumis Q2 FY24: net loss $56.5M; diluted EPS −$23.10

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q
Exhibit 10.11
Material contract

Key figures from this report

These are the numbers Alumis reported for Q2 FY24, the quarter ended Jun 30, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$56.5MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Diluted EPS−$23.10No year-earlier figure tagged10-Q income statement, on EDGAR
  3. Cash and cash equivalents$155.1MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
  4. Cash from operations−$52.3MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Alumis files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Crescent Biopharma CBIO public float $177M, Jun 30, 2025
  2. Editas Medicine EDIT public float $191M, Jun 30, 2025
  3. Omeros OMER public float $172M, Jun 30, 2025
  4. Palvella Therapeutics PVLA public float $197M, Jun 30, 2025
  5. Lexicon Pharmaceuticals LXRX public float $170M, Jun 30, 2025